AR029185A1 - Derivado de naftiridina - Google Patents

Derivado de naftiridina

Info

Publication number
AR029185A1
AR029185A1 ARP000105559A ARP000105559A AR029185A1 AR 029185 A1 AR029185 A1 AR 029185A1 AR P000105559 A ARP000105559 A AR P000105559A AR P000105559 A ARP000105559 A AR P000105559A AR 029185 A1 AR029185 A1 AR 029185A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
substituted
group selected
naftiridine
derivative
Prior art date
Application number
ARP000105559A
Other languages
English (en)
Inventor
Masahiro Iwata
Noriyuki Kawano
Tomofumi Takuwa
Ryota Shiraki
Miki Kobayashi
Makoto Takeuchi
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of AR029185A1 publication Critical patent/AR029185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Derivado de naftiridina representado por la formula general (1), o una sal farmacéuticamente aceptable del mismo y el medicamento que lo contiene como ingrediente activo, donde: R1: alquilo inferior; R2: H o alquilo inferior; R3 y R4: H; R5: cicloalquilo que puede ser sustituido con un grupo seleccionado de R10, o fenilo que puede ser sustituido con un grupo seleccionado entre R10; X: enlace o alquileno inferior; R6: -CO2H, -COO-alquilo inferior, -CONH2, -OH, -NH2, -CN, -C(NH)NH2), -NHC(NH)NH2 o un grupo heterocíclico que puede ser sustituido con un grupo seleccionado de R10, y R10: -halogeno, -alquilo inferior, -CO2H o -CO2-alquilo inferior.
ARP000105559A 1999-10-25 2000-10-23 Derivado de naftiridina AR029185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30254499 1999-10-25

Publications (1)

Publication Number Publication Date
AR029185A1 true AR029185A1 (es) 2003-06-18

Family

ID=17910254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105559A AR029185A1 (es) 1999-10-25 2000-10-23 Derivado de naftiridina

Country Status (16)

Country Link
US (1) US6740662B1 (es)
EP (1) EP1225173B1 (es)
KR (1) KR100699395B1 (es)
CN (1) CN1148369C (es)
AR (1) AR029185A1 (es)
AT (1) ATE305470T1 (es)
AU (1) AU779081B2 (es)
BR (1) BR0014981A (es)
CA (1) CA2385178A1 (es)
DE (1) DE60022893T2 (es)
ES (1) ES2250200T3 (es)
MX (1) MXPA02004122A (es)
PL (1) PL354600A1 (es)
RU (1) RU2240322C2 (es)
TW (1) TWI262919B (es)
WO (1) WO2001030779A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046999A1 (en) * 2002-03-14 2006-03-02 Cristina Alonso-Alija Monocyclic aroylpyridinones as antiinflammatory agents
NZ544697A (en) * 2003-07-22 2009-03-31 Janssen Pharmaceutica Nv Quinolinone derivatives as inhibitors of c-fms kinase
ES2378374T3 (es) 2003-11-20 2012-04-11 Astellas Pharma Inc. Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MX2008010774A (es) * 2006-02-21 2008-09-01 Eisai R&D Man Co Ltd Derivados de 4-(3-benzoilaminofenil)-6, 7-dimetoxi-2-metilaminoqui nazolina.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2652840C (en) 2006-05-24 2014-09-09 Boehringer Ingelheim International Gmbh 2-piperazino-6-chloro-pteridines as pde4-inhibitors for the treatment of inflammatory diseases
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008071964A1 (en) * 2006-12-15 2008-06-19 Astrazeneca Ab Naphthyridine bactericides
EP2123641A4 (en) * 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT
JP5060561B2 (ja) 2007-08-17 2012-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規外用剤
JP5043945B2 (ja) * 2007-08-17 2012-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン誘導体の製造方法
WO2009088054A1 (ja) 2008-01-11 2009-07-16 Astellas Pharma Inc. 精巣の疼痛又は不快感行動及び頻尿併発モデル動物
EP2364983B1 (en) * 2008-11-11 2013-10-23 Jeil Pharmaceutical Co., Ltd. Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10731199B2 (en) * 2011-11-21 2020-08-04 Advanced Liquid Logic, Inc. Glucose-6-phosphate dehydrogenase assays
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2018340475B2 (en) * 2017-09-28 2023-01-19 Transthera Sciences (Nanjing), Inc. PDE9 inhibitor and use thereof
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
WO2020182076A1 (zh) * 2019-03-08 2020-09-17 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂的用途
AU2020242652B2 (en) * 2019-03-15 2023-02-23 Transthera Sciences (Nanjing), Inc. Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
JPS55164682A (en) 1979-06-11 1980-12-22 Yamanouchi Pharmaceut Co Ltd 1-alkyl-2-oxo-2h-1,8-naphthyridine derivative and its preparation
EP0267691A3 (en) * 1986-10-15 1989-08-23 Schering Corporation Use of 1-substituted naphthyridine and pyridopyrazine derivatives for the preparation of medicaments with immunosuppressor activity.
KR950704314A (ko) 1992-12-01 1995-11-17 가와노 다케히코 1,8-나프티리딘-2-온 유도체 및 그 사용 방법(1,8-naphthyridin-2-one derivative and use thereof)
JPH0710875A (ja) * 1993-06-21 1995-01-13 Green Cross Corp:The 選択的ホスホジエステラーゼｉｖ阻害剤
JPH07126268A (ja) * 1993-10-29 1995-05-16 Otsuka Pharmaceut Factory Inc １，８−ナフチリジン誘導体
HUT76980A (hu) 1994-08-29 1998-01-28 Yamanouchi Pharmaceutical Co. Ltd. Új naftiridinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
DE69633059T2 (de) 1995-05-31 2005-08-18 Sumitomo Pharmaceuticals Co., Ltd. Neue naphthyridinderivate.
AU725276B2 (en) 1996-11-26 2000-10-12 Sumitomo Pharmaceuticals Company, Limited Novel naphthyridine derivatives
CA2321237A1 (en) * 1998-02-25 1999-09-02 Masami Muraoka Pyridone derivatives and process for producing the same

Also Published As

Publication number Publication date
CN1382141A (zh) 2002-11-27
EP1225173A4 (en) 2003-08-20
KR20020041477A (ko) 2002-06-01
KR100699395B1 (ko) 2007-03-27
WO2001030779A1 (fr) 2001-05-03
TWI262919B (en) 2006-10-01
US6740662B1 (en) 2004-05-25
CA2385178A1 (en) 2001-05-03
AU779081B2 (en) 2005-01-06
DE60022893D1 (de) 2006-02-09
ATE305470T1 (de) 2005-10-15
EP1225173A1 (en) 2002-07-24
DE60022893T2 (de) 2006-07-13
EP1225173B1 (en) 2005-09-28
MXPA02004122A (es) 2003-02-12
RU2240322C2 (ru) 2004-11-20
BR0014981A (pt) 2002-07-16
ES2250200T3 (es) 2006-04-16
AU7956000A (en) 2001-05-08
CN1148369C (zh) 2004-05-05
PL354600A1 (en) 2004-01-26

Similar Documents

Publication Publication Date Title
AR029185A1 (es) Derivado de naftiridina
ES2171416T3 (es) Remedio contra la trombocitopenia.
AR034897A1 (es) Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
DE60021059D1 (de) Hydrogelpartikel formulierungen
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
DE60023878D1 (de) Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
MY145074A (en) Thiazolidin-4-one derivatives
UY32149A (es) Formulaciones de glifosato que contienen agentes tensioactivos de amidoalquilaminas
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
PA8485101A1 (es) Nuevos antibioticos macrolidos.
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
ES2190422T3 (es) Antagonistas selectivos de receptores de adenosina a2b.
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos
ES2038754T3 (es) Agentes antiarritmicos.

Legal Events

Date Code Title Description
FG Grant, registration